Clinical Psychopharmacology · Paper A
Glutamate modulators (NMDA)
Several drugs act on the NMDA receptorA glutamate receptor in the brain involved in learning and memory, and a target of drugs like ketamine and memantine.Read more →, but each targets it differently and for a different clinical purpose, and one of them, ketamine, produces a strikingly fast antidepressant effect unlike any standard antidepressant. For example, imagine a patient with severe, treatment-resistant depression who improves within hours of a single ketamine dose. In practice, that unusually rapid onset, hours rather than weeks, is the specific reason ketamine is used for treatment-resistant depression.
The NMDA receptorA glutamate receptor in the brain involved in learning and memory, and a target of drugs like ketamine and memantine.Read more → requires both glutamate and glycine binding, plus relief of a magnesium block, to open, making it central to synaptic plasticity and learning. Ketamine is a non-competitive NMDA antagonistA drug that blocks a receptor, stopping it from being activated.Read more → that, at subanaesthetic doses, produces a rapid antidepressant effect in treatment-resistant depression, but also causes dose-related dissociative effects. Esketamine nasal spray holds marketing authorisation for treatment-resistant depression, though NICE has not recommended its routine NHS use in England and Wales due to cost-effectiveness concerns. Memantine is a different, uncompetitive NMDA antagonist with a relatively fast channel exit, letting it block pathological glutamate excitotoxicity while sparing normal signalling; it is licensed for moderate to severe Alzheimer's disease. For example, imagine a patient asking whether esketamine is available to them on the NHS despite being licensed. In practice, this means licensing and NHS funding approval are two separate questions, and a drug can be licensed without being funded.
Several drugs used in psychiatry and neurology act on the (N-methyl-D-aspartate receptor, a subtype of glutamate receptor central to learning and synaptic plasticity), but each targets it differently and for a completely different clinical purpose. Imagine a patient with severe, treatment-resistant depression (depression that has not responded to an adequate trial of standard first-line and second-line antidepressants) who improves within hours of receiving a single dose of ketamine. That unusually rapid onset, hours rather than the several weeks a standard antidepressant needs, is the specific reason ketamine has attracted so much attention, and it is why this receptor sits at the crossroads of two completely different fields: fast-acting antidepressants and dementia care.
In the simplest terms, the is a gate on the surface of a neuron that, when opened, lets positively charged ions flood in and excite the cell. Glutamate (the brain's main excitatory ) is the key that fits the lock, but the gate also needs a second helper chemical, glycine, bound at the same time, and it needs a resting magnesium ion physically dislodged from blocking the channel before it will actually open. A "glutamate modulator (NMDA)" is simply any drug that changes how easily, or how fully, this particular gate opens, either by blocking it directly (an ) or, less commonly in exam-relevant drugs, by helping it open more easily (an or ).
The single thing beginners get wrong is assuming that because two drugs hit the same receptor, they must do the same job. They don't. Ketamine and memantine both block the , yet one is a rapid-acting antidepressant used for treatment-resistant depression and the other is an antidementia drug for moderate to severe Alzheimer's disease. Giving a frail dementia patient ketamine instead of memantine would be clinically inappropriate: ketamine's dissociative and abuse-potential profile is unsuited to routine dementia treatment, and it carries no licensed indication for Alzheimer's disease at all. The reason two "NMDA " can behave so differently comes down to exactly how, and how strongly, each one blocks the channel, which is the first-principles question the next section answers.
The needs both glutamate and glycine to bind, plus relief of that resting magnesium block, before it will open, which makes it central to synaptic plasticity (the strengthening or weakening of connections between neurons that underlies learning and memory). Because the channel is normally plugged by magnesium at rest, it only opens properly during genuinely strong, sustained excitatory signalling, exactly the kind of signal that matters for learning. Two features of a blocking drug determine what happens clinically: how the drug sits in the channel, and how quickly it leaves again.
Ketamine is a non-competitive NMDA antagonist (a drug that blocks the receptor's channel from the inside, rather than competing with glutamate for its binding site) that binds strongly and stays in place for a relatively long time. Memantine is an uncompetitive NMDA antagonist with a much faster channel exit, meaning it only blocks the channel when it is already pathologically over-activated and lets go quickly the rest of the time. That single kinetic difference, slow versus fast unbinding, is why memantine can quietly dampen down the excess, damaging glutamate signalling seen in Alzheimer's disease (excitotoxicity: nerve cell damage caused by overexposure to excitatory ) while leaving the normal, moment-to-moment signalling needed for everyday brain function almost untouched, whereas ketamine's firmer, longer block produces a much more dramatic acute effect on brain function, both therapeutically and in terms of .
Ketamine. Given at subanaesthetic doses, doses well below those used for general anaesthesia (research and clinical use for depression typically uses around 0.5 mg/kg by slow intravenous infusion, far below anaesthetic dosing), ketamine produces a rapid antidepressant effect specifically in treatment-resistant depression. This speed stands in sharp contrast to SSRIs, which typically take several weeks of treatment before a clear response can be judged. The trade-off is dose-related dissociative effects (a sense of detachment from one's own body, thoughts, or surroundings) that become more prominent as the dose rises, plus a recognised abuse liability, so ketamine for depression is given under supervision in a monitored setting rather than as a take-home prescription.
Esketamine. Esketamine nasal spray (a specific isomer of ketamine delivered as a nasal medication) holds a marketing authorisation, or licence, for treatment-resistant depression. NICE (National Institute for Health and Care Excellence) has not recommended its routine use on the NHS in England and Wales, citing cost-effectiveness concerns rather than any doubt about whether it works. Licensing and NHS funding approval are two separate questions: a drug can be legally licensed and prescribable in principle without being funded for routine NHS use, and patients (and even some clinicians) often conflate the two.
Memantine. Memantine is licensed specifically for moderate to severe Alzheimer's disease, usually dosed once daily and titrated up toward a standard maintenance dose of 20 mg/day. Because its fast channel exit spares normal signalling, it does not produce ketamine's dissociative effects or abuse potential at therapeutic doses, and it is not used for depression at all, despite sharing the same receptor target as ketamine.
Three things get muddled with NMDA modulators, and it is worth pulling each one apart cleanly.
First, benzodiazepines act on a completely different receptor, -A, to enhance inhibitory signalling rather than block excitatory glutamate transmission; they calm the brain down by boosting the brake pedal, not by loosening the accelerator's grip the way an NMDA does.
Second, phencyclidine (PCP), a recreational drug of misuse, is pharmacologically a close cousin of ketamine: it is also a non-competitive NMDA . This is exactly why ketamine and PCP intoxication can produce psychosis-like states, and it underpins the "NMDA hypofunction" hypothesis of , the idea that under-functioning of , not just excess dopamine, contributes to psychotic symptoms. Don't mistake recreational ketamine or PCP misuse for a primary psychotic illness without taking a careful substance history.
Third, and easy to miss, is anti-NMDA-receptor encephalitis, an autoimmune condition where the patient's own antibodies attack the itself, rather than any drug being involved at all. It classically presents with a mix of acute psychiatric symptoms (psychosis, agitation, ), seizures, and abnormal movements, often in a young woman, and is well known for its association with an underlying ovarian teratoma. Because the psychiatric symptoms can dominate the early picture, this condition is a genuine look-alike for a primary psychotic or mood disorder, and missing it means missing a treatable autoimmune illness.
Diagnosis here means three quite different things depending on which corner of this topic you're in. Treatment-resistant depression, the indication for ketamine and esketamine, is established clinically: a patient must have failed an adequate trial (correct dose, correct duration) of standard antidepressants, usually at least two such trials, before being considered for a specialist, secondary-care ketamine or esketamine pathway. Alzheimer's disease, memantine's indication, is diagnosed through a combination of history (including collateral history from family about functional decline), bedside cognitive testing such as the , and structural brain imaging to exclude other reversible or alternative causes of cognitive decline; there is no single blood test or scan that alone makes the diagnosis. Anti-NMDA-receptor encephalitis is confirmed by finding anti- antibodies in the cerebrospinal fluid, supported by MRI and EEG changes and a search for an underlying tumour such as an ovarian teratoma; this is the one diagnosis on this page made by a specific antibody test rather than by clinical pattern-matching alone.
Management splits cleanly along the same three lines. For treatment-resistant depression, ketamine and esketamine are used within specialist, closely monitored secondary or tertiary care services, with esketamine's licensed status but non-routine NHS funding meaning that, in practice, access usually depends on local commissioning arrangements or specialist mood disorder services rather than a straightforward GP prescription. For Alzheimer's disease, NICE's dementia care guideline (NG97) recommends memantine as an option for moderate to severe disease, either alone or added on to an acetylcholinesterase inhibitor (a different class of antidementia drug, such as donepezil, that works by boosting acetylcholine rather than blocking ), reflecting how the two drug classes are complementary rather than interchangeable. For anti-NMDA-receptor encephalitis, management is immunological, not psychiatric: first-line treatment is with steroids, intravenous immunoglobulin, or plasma exchange, together with removal of any underlying tumour if one is found, delivered jointly with neurology.
The trap the exam loves is testing whether you'll wrongly assume "NMDA " means one uniform clinical effect. It doesn't: the speed and firmness of the channel block is what separates ketamine's fast, dissociative, abuse-prone antidepressant action from memantine's slow, gentle, -free antidementia action, even though both sit on the exact same receptor. A second high-yield pearl: if a young patient presents with a rapid-onset mix of psychiatric symptoms, seizures, and abnormal movements, think anti-NMDA-receptor encephalitis and antibody testing before settling on a primary psychiatric diagnosis.
Ketamine and esketamine block the firmly to treat depression fast but with real and abuse risks, memantine blocks it gently and quickly-reversibly to treat Alzheimer's without those risks, and anti-NMDA-receptor antibodies attacking that same receptor can themselves mimic a primary psychiatric illness.